DUBLIN--(BUSINESS WIRE)--The "Global Gene Therapy Market - Analysis By Vector Type, By Application, By Region, By Country (2020 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
Global Gene Therapy Market was valued at USD 1221.84 Million in the year 2019.
Escalating number of cases related to various chronic diseases including Cancer, Cardiovascular and Neurological Disorders, Alzheimer's and Sickle Cell Diseases, with companies investing heavily in incorporating advanced technology supported by growing collaboration between bio-pharma companies and research institutes to advance in the field of Gene therapy, has been anticipated to infuse growth in the market for Gene Therapy during the forecast period of 2020-2025.
Under the Vector Type segment, AAV vectors, followed by Retrovirus & Gammaretrovirus and Lentivirus, are anticipated to witness the largest market share owing to growing investment in adeno-associated viral (AAV) vectors to advance research programs against strategically selected cell targets. Increasing prevalence of various diseases across the globe will further accelerate the gene therapy market growth during the coming years.
Among the regions, North America, followed by Europe and Asia Pacific, will experience remarkable market share owing to the presence of various leading global companies including Orchard Therapeutics, Voyager Therapeutics, and Spark Therapeutics. With companies investing in adoption of advanced technology supported by enhanced focus on expanding product pipeline by manufacturers to advance in the field of Gene Therapy will further facilitate the market growth during the forecast period.
Scope of the Report
- The report analyses Gene Therapy market By Value.
- The report analyses Gene Therapy Market By Vector Type (Lentivirus, AAV, Retrovirus & Gammaretrovirus, Others).
- The report further assesses the Gene Therapy market By Application (Neurological Disorders, Cancer, Cardiovascular Diseases, Others).
- The Global Gene Therapy Market has been analysed By Region (North America, Europe, and Asia Pacific) and By Country (United States, Canada, Germany, France, United Kingdom, Italy, China, Japan, India, South Korea).
- The key insights of the report have been presented through the frameworks of Major Mergers & Acquisitions, Technological Innovations, and Role of Companies during COVID-19 Pandemic with and Product Pipeline of Leading Companies. Also, the attractiveness of the market has been presented By Region, Vector Type and Application. Additionally, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The companies analysed in the report include Voyager Therapeutics, Novartis AG, Spark Therapeutics Inc., MoldMed S.P.A., Orchard Therapeutics PLC, Alnylam Pharmaceuticals Inc., AnGes Inc., Akcea Therapeutics, BlueBird Bio Inc., and Sarepta Therapeutics.
- The report presents the analysis of Gene Therapy market for the historical period of 2015-2019 and the forecast period of 2020-2025.
Key Topics Covered:
1. Research Methodology and Executive Summary
1.1 Research Methodology
1.2 Executive Summary
2. Strategic Recommendations
3. Gene Therapy Market: Product Outlook
4. Global Gene Therapy Market: Sizing and Forecast
4.1 Market Size, By Value, Year 2015-2025
5. Global Gene Therapy Market Segmentation - By Vector Type, and By Application
5.1 Competitive Scenario of Global Gene Therapy Market: By Vector Type
5.1.1 Lentivirus - Market Size and Forecast (2015-2025)
5.1.2 AAV - Market Size and Forecast (2015-2025)
5.1.3 Retrovirus & Gammaretrovirus - Market Size and Forecast (2015-2025)
5.1.4 Others - Market Size and Forecast (2015-2025)
5.2 Competitive Scenario of Global Gene Therapy Market: By Application
5.2.1 Neurological Disorders - Market Size and Forecast (2015-2025)
5.2.2 Cancer - Market Size and Forecast (2015-2025)
5.2.3 Cardiovascular Diseases - Market Size and Forecast (2015-2025)
5.2.4 Others - Market Size and Forecast (2015-2025)
6. Global Gene Therapy Market: Regional Analysis
6.1 Competitive Scenario of Global Gene Therapy Market: By Region
7. North America Gene Therapy Market: An Analysis (2015-2025)
7.1 North America Gene Therapy Market: Size and Forecast (2015-2025), By Value
7.2 North America Gene Therapy Market - Prominent Companies
7.3 Market Segmentation By Vector Type (Lentivirus, AAV, Retrovirus & Gammaretrovirus and Others)
7.4 Market Segmentation By Application (Neurological Disorders, Cancer, Cardiovascular Diseases and Others)
7.5 North America Gene Therapy Market: Country Analysis
7.6 Market Opportunity Chart of North America Gene Therapy Market - By Country, By Value, 2025
7.7 Competitive Scenario of North America Gene Therapy Market : By Country
7.8 United States Gene Therapy Market: Size and Forecast (2015-2025), By Value
7.9 United States Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)
7.10 Canada Gene Therapy Market: Size and Forecast (2015-2025), By Value
7.11 Canada Gene Therapy Market Segmentation - By Vector Type, and By Application (2015-2025)
8. Europe Gene Therapy Market: An Analysis (2015-2025)
9. Asia Pacific Gene Therapy Market: An Analysis (2015-2025)
10. Global Gene Therapy Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Gene Therapy Market - By Vector Type, 2025
11.2 Market Attractiveness Chart of Global Gene Therapy Market - By Application, 2025
11.3 Market Attractiveness Chart of Global Gene Therapy Market - By Region, 2025
12. Competitive Landscape
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers During COVID-19
12.2 Product Pipeline of Leading Gene Therapy Companies
12.3 Market Share Analysis
13. Company Analysis (Business Description, Financial Analysis, Business Strategy)
13.1 Voyager Therapeutics
13.2 Novartis AG
13.3 Spark Therapeutics Inc.
13.4 MoldMed S.P.A.
13.5 Orchard Therapeutics PLC
13.6 Alnylam Pharmaceuticals Inc.
13.7 AnGes Inc.
13.8 Akcea Therapeutics
13.9 BlueBird Bio Inc.
13.10 Sarepta Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/fvdzkj
